These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 8531308

  • 1. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM.
    JAMA; 1996 Jan 10; 275(2):128-33. PubMed ID: 8531308
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV.
    Metabolism; 2000 Feb 10; 49(2):167-77. PubMed ID: 10690940
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis.
    Kidney Int; 2002 Apr 10; 61(4):1469-74. PubMed ID: 11918754
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM.
    Am J Med; 1998 Feb 10; 104(2):137-43. PubMed ID: 9528731
    [Abstract] [Full Text] [Related]

  • 10. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG, Ishisaka DY, Luo D, Ntanios F, Wun CC.
    Am J Cardiol; 2007 Aug 01; 100(3):445-9. PubMed ID: 17659926
    [Abstract] [Full Text] [Related]

  • 11. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M.
    J Clin Lipidol; 2011 Aug 01; 5(6):483-92. PubMed ID: 22108152
    [Abstract] [Full Text] [Related]

  • 12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov 01; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.
    J Am Coll Cardiol; 2012 Jun 19; 59(25):2344-53. PubMed ID: 22463922
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H.
    Am J Cardiol; 2002 Feb 01; 89(3):268-75. PubMed ID: 11809427
    [Abstract] [Full Text] [Related]

  • 18. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.
    Bakker-Arkema RG, Best J, Fayyad R, Heinonen TM, Marais AD, Nawrocki JW, Black DM.
    Atherosclerosis; 1997 May 01; 131(1):17-23. PubMed ID: 9180240
    [Abstract] [Full Text] [Related]

  • 19. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW, Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.
    Clin Ther; 2004 Sep 01; 26(9):1388-99. PubMed ID: 15531001
    [Abstract] [Full Text] [Related]

  • 20. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB, Simvastatin Atorvastatin HDL Study Group.
    Curr Med Res Opin; 2001 Sep 01; 17(1):43-50. PubMed ID: 11464446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.